Arcellx, Inc. (ACLX) can buy. Click on Rating Page for detail.
The price of Arcellx, Inc. (ACLX) is 51.92 and it was updated on 2024-04-27 07:00:41.
Currently Arcellx, Inc. (ACLX) is in undervalued.
News |
---|
Arcellx, Inc. (ACLX) Q4 Earnings and Revenues Surpass Estimates
|
The 3 Biotech Stocks That Could Make Your February Unforgettable
|
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
|
Pharma's Frontline: 3 Stocks Driving Revolutionary Drug Development
|
3 Biotech Stocks That Could Be Multibaggers in the Making
|
StockPrice Release |
---|
News |
---|
Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead
|
Arcellx stock climbs on Gilead investment
|
Arcellx's stock set to surge after Gilead makes $200 million investment at a 30% premium
|
Is a Surprise Coming for Arcellx (ACLX) This Earnings Season?
|
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
|
Are Medical Stocks Lagging Arcellx (ACLX) This Year?
|
7 Biotech Stocks to Get In Now Before Investors Catch On
|
Is Arcellx (ACLX) Stock Outpacing Its Medical Peers This Year?
|
Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs
|
Wall Street Analysts Believe Arcellx, Inc. (ACLX) Could Rally 35.56%: Here's is How to Trade
|
Arcellx (ACLX) Down on Hold for Lead Program CART-ddBCMA
|
Arcellx price target slashed, stock takes a hit as FDA puts hold on clinical trial following patient death
|
Arcellx, Inc. (ACLX) Reports Q1 Loss, Misses Revenue Estimates
|
5 Stocks With Recent Price Strength That Still Have Upside
|
Arcellx, Inc. (ACLX) is a Great Momentum Stock: Should You Buy?
|
Arcellx, Inc. (ACLX) Upgraded to Strong Buy: Here's What You Should Know
|
New Strong Buy Stocks for April 21st
|
New Strong Buy Stocks for April 17th
|
Best Momentum Stocks to Buy for April 11th
|
New Strong Buy Stocks for April 11th
|
Wall Street Analysts Predict a 29.58% Upside in Arcellx, Inc. (ACLX): Here's What You Should Know
|
Earnings Estimates Moving Higher for Arcellx, Inc. (ACLX): Time to Buy?
|
Arcellx, Inc. (ACLX) Reports Q4 Loss, Misses Revenue Estimates
|
Is a Surprise Coming for Arcellx (ACLX) This Earnings Season?
|
Arcellx: The Gilead Deal Derisks And Proves Their Technology
|
Arcellx flies on $325M deal with Gilead's Kite for multiple myeloma treatment
|
Why Is Arcellx (ACLX) Stock Up 25% Today?
|
Gilead to co-develop Arcellx's multiple myeloma drug
|
These Are the 10 Best-Performing IPOs in 2022 Through October
|
Arcellx: Promising Up And Coming Player In The CAR-T Space
|
Arcellx: The Best Is Yet To Come
|
Arcellx Announces Participation at the Barclays Global Healthcare Conference
|
U.S. IPO Weekly Recap: The February IPO Market Kicks Off With 2 Biotechs
|
CAR-T Player Arcellx Raises $123M Via Initial Public Offering, Opens Trading At $19
|
Arcellx sets IPO terms, looks to raise up to $140.3 million
|